RASAGILINE MARKET 

INTRODUCTIONRASAGILINE MARKET

Parkinson's disease symptoms are treated with rasagiline alone or in conjunction with other drugs (a slowly progressing disease of the nervous system causing a fixed face without expression, tremor at rest, slowing of movements, walking with shuffling steps, stooped posture and muscle weakness).

Rasagiline is a member of the monoamine oxidase (MAO) type B inhibitors drug class. It functions by raising the levels of specific organic compounds in the brain.

Negative effects-It's possible to have lightheadedness, drowsiness, joint discomfort, heartburn, nausea, dry mouth, weight loss, or stomach/abdominal pain. Inform your physician or pharmacist right away if any of these side effects persist or worsen.

It is used either alone or in conjunction with other drugs (such levodopa/carbidopa) to treat the symptoms of Parkinson's disease.

It can alleviate signs including trembling, stiffness, and trouble moving. Additionally, it can help to cut down on "off" time (periods of slow movement or stiffness). Rasagiline is a type of drug known as an MAO inhibitor.

It functions by increasing the levels of specific natural chemicals in the brain (such as dopamine, norepinephrine, serotonin).

The effects of one medicine last about a week, whereas those of another last around two weeks. However, over the course of eight weeks, people see a noticeable improvement in their symptoms. Take the medication at the same time each day to get the best outcomes.

RASAGILINE MARKET SIZE AND FORECAST

Global RASAGILINE market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.

RASAGILINE MARKETMARKET DYNAMICS

Rasagiline Tablets, 0.5 mg and 1 mg, a generic version of the reference listed medication, Teva's Azilect Tablets, was made available in the United States by Mylan N.V.

The U.S. Food and Drug Administration (FDA) granted final approval to Mylan's Abbreviated New Drug Application (ANDA) for this medication, which is indicated for the treatment of Parkinson's disease.

The multinational pharmaceutical business Mylan is dedicated to raising the bar for healthcare. Working together globally to give people access to high-quality healthcare, they innovate to fill unmet needs, practise dependability and service excellence, behave morally rather than expediently, and have a positive impact on the future through committed global leadership.

The US Food & Drug Administration has given final approval to Indoco Remedies' Abbreviated New Drug Application (ANDA) for Rasagiline 0.5 mg and 1 mg tablets (USFDA). Parkinson's disease is treated with rasagiline. The size of this product's US market.

RASAGILINE MARKETCOMPANY PROFILE

• Teva Pharmaceutical Industries.
• Maithili Life Sciences
• Metrochem API Pvt Ltd
• ALKEM LABS LTD
• Trumac Healthcare
• Alvogen

THISRASAGILINE MARKETREPORT WILL ANSWER FOLLOWING QUESTIONS

1. How many RASAGILINE are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global RASAGILINE and key vendor selection criteria
3. Where is the RASAGILINE manufactured? What is the average margin per unit?
4. Market share of Global RASAGILINE market manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture Global RASAGILINE in-house
6. key predictions for next 5 years in Global RASAGILINE market
7. Average B-2-B RASAGILINE market price in all segments
8. Latest trends in RASAGILINE market, by every market segment
9. The market size (both volume and value) of the RASAGILINE market in 2024-2030 and every year in between?
10. Production breakup of RASAGILINE market, by suppliers and their OEM relationship